Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Ischemic heart disease is a leading cause of death worldwide, and coronary artery bypass grafting (CABG) is a major treatment. Landiolol is an ultra-short-acting beta-antagonist known to prevent postoperative atrial fibrillation. However, the effectiveness of intraoperative landiolol on mortality remains unknown. This study aimed to evaluate the association between intraoperative landiolol use and the in-hospital mortality in patients undergoing CABG.
Methods: To conduct this retrospective cohort study, we used data from the Japanese Diagnosis Procedure Combination inpatient database. All patients who underwent CABG during hospitalization between July 1, 2010, and March 31, 2020, were included. Patients who received intraoperative landiolol were defined as the landiolol group, whereas the other patients were defined as the control group. The primary outcome was in-hospital mortality. Propensity score matching was used to compare the landiolol and control groups.
Results: In total, 118,506 patients were eligible for this study, including 25,219 (21%) in the landiolol group and 93,287 (79%) in the control group. One-to-one propensity score matching created 24,893 pairs. After propensity score matching, the in-hospital mortality was significantly lower in the landiolol group than that in the control group (3.7% vs 4.3%; odds ratio 0.85; 95% confidence interval 0.78 to 0.94; P = .010).
Conclusions: Intraoperative landiolol use was associated with decreased in-hospital mortality in patients undergoing CABG. Further randomized controlled trials are required to confirm these findings.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1213/ANE.0000000000006741 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A case of abnormal hypertension and Takotsubo syndrome caused by adrenal hemostasis using an electric scalpel: a case report.
JA Clin Rep
May 2025
Department of Anesthesiology, Rinku General Medical Center, Rinku Ourai Kita 2-23, Izumisanoshi, Osaka, 598-8577, Japan.
Background: Although intraoperative adrenal hemostasis by cauterization can cause abnormal hypertension, hemodynamic condition is usually normalized in a few minutes without any postoperative complications. We present a rare case of abnormal hypertension caused by adrenal hemostasis using an electric scalpel, which resulted in cardiac dysfunction: Takotsubo syndrome.
Case Presentation: A 74-year-old woman received open hepatectomy for a hepatic tumor.
Heart Rate Control with Landiolol Hydrochloride in Infants and Neonates During Cardiac Surgery.
Pediatr Cardiol
March 2025
AOP Orphan Pharmaceuticals GmbH, Vienna, Austria.
Perioperative tachyarrhythmias are common in children undergoing cardiac surgery, contributing to significant mortality and morbidity. Landiolol, an ultrashort-acting beta-blocker, offers selective heart rate (HR) control in pediatric patients with tachycardia during cardiac surgery. The LANDI-cardioPed study assessed landiolol's safety and efficacy in children during cardiac surgery.
View Article and Find Full Text PDFAssessing the Risks and Benefits of Hypotensive Anesthesia and Piezosurgical Instruments in Bimaxillary Surgery.
Cureus
August 2024
Oral and Maxillofacial Surgery, National Defense Medical College, Tokorozawa, JPN.
The challenge in bimaxillary surgery lies in significant intraoperative bleeding, prompting various strategies to minimize blood loss. Among the methods considered for controlling intraoperative bleeding, hypotensive anesthesia and the use of piezosurgical instruments (Osada, Tokyo, Japan) have been explored. However, hypotensive anesthesia may have adverse effects on cardiac function, and surgical time is likely to be prolonged when using piezosurgical instruments.
View Article and Find Full Text PDFAn Overview of the Pharmacokinetics and Pharmacodynamics of Landiolol (an Ultra-Short Acting β1 Selective Antagonist) in Atrial Fibrillation.
Pharmaceutics
April 2024
Department of Internal Medicine, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
Landiolol is an ultra-short-acting, selective β1-adrenergic receptor blocker that was originally approved in Japan for the treatment of intraoperative tachyarrhythmias. It has gained attention for its use in the management of tachyarrhythmias and perioperative tachycardia, especially atrial fibrillation for both cardiac and non-cardiac surgeries. It can be the ideal agent for heart rate control due to its high β1-selectivity, potent negative chronotropic effect, a limited negative inotropic potential, and an ultrashort elimination half-life (around 4 min); moreover, it may have a potential therapeutic effects for sepsis and pediatric patients.
View Article and Find Full Text PDFAssociation Between Intraoperative Landiolol Use and In-Hospital Mortality After Coronary Artery Bypass Grafting: A Nationwide Observational Study in Japan.
Anesth Analg
December 2023
Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
Article Synopsis
- Ischemic heart disease is a major global health issue, with coronary artery bypass grafting (CABG) being a common treatment, and landiolol is a beta-antagonist believed to reduce postoperative complications like atrial fibrillation.
- This study analyzed data from a large cohort of CABG patients between 2010 and 2020, comparing those given landiolol during surgery to those who weren't, focusing on their in-hospital mortality rates.
- Results indicated that patients who received intraoperative landiolol had a significantly lower in-hospital mortality rate (3.7%) compared to those in the control group (4.3%), suggesting that landiolol may improve outcomes for CABG patients, although further research